Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 4 Analysis of the specificity of haplogroup distribution in VSCC cohort.

From: Mitochondrial genotype in vulvar carcinoma - cuckoo in the nest

    

1

2

3

4

5

6

Positive

Negative

% positive

p vs PP

p vs NP

p vs COMB

p vs CENT

p vs HNC

p vs EA

H

7

18

28%

0.502

0.102

0.152

0.023 U

0.39

0.173

I

0

25

0%

1

1

1

0.194

1

1

J

1

24

4%

0.697

0.7

0.712

1

1

0.191

K

3

22

12%

0.381

0.067

0.092

0.693

0.333

1

NN

1

24

4%

1

0.547

0.552

ND

0.613

0.61

T

3

22

12%

1

1

1

0.712

1

0.668

U

8

17

32%

0.3

0.052

0.104

0.01 O

0.761

0.764

V

0

25

0%

0.368

0.385

0.389

1

1

1

W

2

23

8%

0.147

0.254

0.209

0.051

0.218

1

X

0

25

0%

1

1

1

1

1

1

Total

25

        
  1. Haplogroup distribution in VSCC patients cohort was were compared with 1) the general Polish population (p vs PP) [38], 2) population from the Northern Poland (p vs NP) [39], 3) those two populations combined (p vs COMB), 4) cancer free centenarians cohort (p vs CENT), 5) head and neck tumors patients cohort (p vs HNC), and 6) endometrial adenocarcinoma patients cohort (p vs EA) [11]. % positive - percentage of patients carrying particular haplotype in VSCC cohort. Significant differences - bolded: O - overrepresented in VSCC cohort, U - underrepresented in VSCC cohort.